{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=9",
    "query": {
      "condition": "Cancer, Advanced",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 9813,
    "total_pages": 982,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer%2C+Advanced&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T16:25:55.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00336856",
      "title": "Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer",
        "Rectum Cancer"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2006-06",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2016-07-12",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336856"
    },
    {
      "nct_id": "NCT00413322",
      "title": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor"
      ],
      "interventions": [
        {
          "name": "belinostat",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil (5-FU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valerio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-09",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-08",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Portsmouth",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413322"
    },
    {
      "nct_id": "NCT00022529",
      "title": "BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "BMS-214662",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2001-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-25",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022529"
    },
    {
      "nct_id": "NCT04111445",
      "title": "Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ADG116",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adagene Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-08-29",
      "completion_date": "2021-04-27",
      "has_results": false,
      "last_update_posted_date": "2021-09-10",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04111445"
    },
    {
      "nct_id": "NCT04892472",
      "title": "EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NovoTTF-200T",
          "type": "DEVICE"
        },
        {
          "name": "Pembrolizumab (MK-3475) 200 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "NovoCure GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-07-12",
      "completion_date": "2025-01-10",
      "has_results": false,
      "last_update_posted_date": "2025-04-23",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04892472"
    },
    {
      "nct_id": "NCT06458712",
      "title": "Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)"
      ],
      "interventions": [
        {
          "name": "DSB2455",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke Street Bio Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2024-11-21",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 4,
      "location_summary": "Sacramento, California • New Haven, Connecticut • New York, New York + 1 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06458712"
    },
    {
      "nct_id": "NCT05458219",
      "title": "A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Unresectable or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "IBI343",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRINOX/mFOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innovent Biologics (Suzhou) Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 470,
      "start_date": "2022-10-26",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 3,
      "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05458219"
    },
    {
      "nct_id": "NCT00943319",
      "title": "Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-03",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2019-02-04",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943319"
    },
    {
      "nct_id": "NCT00806156",
      "title": "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "NKTR-102 q14d",
          "type": "DRUG"
        },
        {
          "name": "NKTR-102 q21d",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 178,
      "start_date": "2008-10",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-12",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 11,
      "location_summary": "Highland, California • Los Angeles, California • Newport Beach, California + 8 more",
      "locations": [
        {
          "city": "Highland",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00806156"
    },
    {
      "nct_id": "NCT03516981",
      "title": "A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Favezelimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Quavonlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2018-10-01",
      "completion_date": "2025-06-13",
      "has_results": true,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-11-05T16:25:55.309Z",
      "location_count": 19,
      "location_summary": "Tempe, Arizona • Sacramento, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03516981"
    }
  ]
}